Denali Therapeutics Stock Price, News & Analysis (NASDAQ:DNLI)

$23.02 -0.66 (-2.79 %)
(As of 02/22/2018 05:34 AM ET)
Previous Close$23.68
Today's Range$22.72 - $24.78
52-Week Range$14.72 - $25.79
Volume176,724 shs
Average Volume201,439 shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics logoDenali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees125
Outstanding Shares87,980,000

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Where is Denali Therapeutics' stock going? Where will Denali Therapeutics' stock price be in 2018?

4 brokerages have issued twelve-month target prices for Denali Therapeutics' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Denali Therapeutics' stock price to reach $24.00 in the next twelve months. View Analyst Ratings for Denali Therapeutics.

Who are some of Denali Therapeutics' key competitors?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the folowing people:

  • Marc Tessier-Lavignec Ph.D., Chairman of the Board, Co-Founder
  • Ryan Watts, President, Chief Executive Officer, Co-Founder, Director
  • Alexander Schuth, Co-Founder, Chief Operating Officer, Head of Corporate Development
  • Steve E. Krognes, Chief Financial Officer (Age 48)
  • Carole Ho M.D., Chief Medical Officer

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

When did Denali Therapeutics' quiet period expire?

Denali Therapeutics' quiet period expired on Wednesday, January 17th. Denali Therapeutics had issued 13,888,888 shares in its IPO on December 8th. The total size of the offering was $249,999,984 based on an initial share price of $18.00. During Denali Therapeutics' quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who owns Denali Therapeutics stock?

Denali Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Crestline Management LP (23.39%), Flagship Pioneering Inc. (10.14%), Artal Group S.A. (0.57%), Bamco Inc. NY (0.56%), Bridger Management LLC (0.36%) and Allianz Asset Management GmbH (0.23%). View Institutional Ownership Trends for Denali Therapeutics.

Who bought Denali Therapeutics stock? Who is buying Denali Therapeutics stock?

Denali Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Crestline Management LP, Flagship Pioneering Inc., Artal Group S.A., Bamco Inc. NY, Bridger Management LLC, Allianz Asset Management GmbH, Goldman Sachs Group Inc. and NF Trinity Capital Hong Kong Ltd. View Insider Buying and Selling for Denali Therapeutics.

How do I buy Denali Therapeutics stock?

Shares of Denali Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of Denali Therapeutics stock can currently be purchased for approximately $23.02.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $2.08 billion. Denali Therapeutics employs 125 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.


MarketBeat Community Rating for Denali Therapeutics (DNLI)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Denali Therapeutics (NASDAQ:DNLI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 2.752.75N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00N/AN/A
Price Target Upside: 53.45% upside53.45% upsideN/AN/A

Denali Therapeutics (NASDAQ:DNLI) Consensus Price Target History

Price Target History for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ:DNLI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2018Evercore ISIInitiated CoverageOutperform -> Outperform$23.00MediumView Rating Details
1/2/2018Goldman Sachs GroupInitiated CoverageNeutral -> NeutralHighView Rating Details
1/2/2018Morgan StanleyInitiated CoverageOverweight -> Overweight$25.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$24.00HighView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Denali Therapeutics (NASDAQ:DNLI)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Denali Therapeutics (NASDAQ:DNLI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.47 EPS
Next Year EPS Consensus Estimate: $-0.87 EPS

Dividends

Dividend History for Denali Therapeutics (NASDAQ:DNLI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Denali Therapeutics (NASDAQ DNLI) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 23.56%
Insider Trades by Quarter for Denali Therapeutics (NASDAQ:DNLI)
Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ DNLI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Douglas K BrattonMajor ShareholderBuy275,000$18.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Denali Therapeutics (NASDAQ DNLI) News Headlines

Source:
DateHeadline
Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 12 at 11:28 PM
Zacks: Denali Therapeutics Inc (DNLI) Given $24.67 Average Target Price by AnalystsZacks: Denali Therapeutics Inc (DNLI) Given $24.67 Average Target Price by Analysts
www.americanbankingnews.com - February 9 at 9:28 PM
Denali Therapeutics (DNLI), Lonza Pharma & Biotech Announce Pact to Develop and Produce Biologic MedicinesDenali Therapeutics (DNLI), Lonza Pharma & Biotech Announce Pact to Develop and Produce Biologic Medicines
www.streetinsider.com - February 9 at 9:08 AM
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic MedicinesDenali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
finance.yahoo.com - February 8 at 4:28 PM
Zacks: Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Denali Therapeutics Inc (DNLI) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 25 at 11:40 AM
Analyzing Denali Therapeutics (DNLI) & Its RivalsAnalyzing Denali Therapeutics (DNLI) & Its Rivals
www.americanbankingnews.com - January 19 at 9:30 PM
 Brokerages Anticipate Denali Therapeutics Inc (DNLI) Will Announce Earnings of -$0.30 Per Share Brokerages Anticipate Denali Therapeutics Inc (DNLI) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - January 19 at 11:38 AM
Short Interest in Denali Therapeutics Inc (DNLI) Expands By 1,101.8%Short Interest in Denali Therapeutics Inc (DNLI) Expands By 1,101.8%
www.americanbankingnews.com - January 12 at 2:38 AM
Denali Therapeutics Incs Quiet Period Set To End  on January 17th (NASDAQ:DNLI)Denali Therapeutics Inc's Quiet Period Set To End on January 17th (NASDAQ:DNLI)
www.americanbankingnews.com - January 10 at 1:04 AM
Analysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) Earnings Per ShareAnalysts Anticipate Denali Therapeutics Inc (DNLI) to Announce ($0.30) Earnings Per Share
www.americanbankingnews.com - January 9 at 7:58 AM
Denali Therapeutics (DNLI) Reports Collaboration with Takeda Pharmaceutical to Develop & Commercial for Neurodegenerative DiseasesDenali Therapeutics (DNLI) Reports Collaboration with Takeda Pharmaceutical to Develop & Commercial for Neurodegenerative Diseases
www.streetinsider.com - January 5 at 8:15 AM
Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative DiseasesTakeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
finance.yahoo.com - January 5 at 8:15 AM
Snow, Skiing, And A Biotech VCs Outlook For 2018Snow, Skiing, And A Biotech VC's Outlook For 2018
finance.yahoo.com - January 4 at 6:30 PM
Denali Therapeutics (DNLI) and Its Peers Critical ContrastDenali Therapeutics (DNLI) and Its Peers Critical Contrast
www.americanbankingnews.com - January 4 at 11:30 AM
Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 4 at 4:02 AM
Analyst: Denali Therapeutics Neuroscience Work Could Lead To Near-Term UpsideAnalyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside
finance.yahoo.com - January 3 at 6:34 PM
3 Key Questions For Denali Therapeutics Investors3 Key Questions For Denali Therapeutics Investors
finance.yahoo.com - January 3 at 7:56 AM
Denali Therapeutics Inc. (DNLI) Coverage Initiated by Analysts at Evercore ISIDenali Therapeutics Inc. (DNLI) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - January 2 at 8:48 AM
Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s DiseaseDenali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
finance.yahoo.com - December 20 at 6:28 PM
Insider Buying: "Denali Therapeutics Inc." (DNLI) Major Shareholder Buys 275,000 Shares of StockInsider Buying: "Denali Therapeutics Inc." (DNLI) Major Shareholder Buys 275,000 Shares of Stock
www.americanbankingnews.com - December 14 at 5:34 PM
Bitcoin shorts face massive losses if Winklevoss’s call hits the markBitcoin shorts face massive losses if Winklevoss’s call hits the mark
finance.yahoo.com - December 11 at 8:04 AM
Denali Therapeutics celebrates its IPO at the Nasdaq MarketSiteDenali Therapeutics celebrates its IPO at the Nasdaq MarketSite
www.cnbc.com - December 10 at 8:06 AM
Denali Therapeutics Enters the Market With a BangDenali Therapeutics Enters the Market With a Bang
247wallst.com - December 10 at 8:06 AM
Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO - GlobeNewswire (press release)Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO - GlobeNewswire (press release)
globenewswire.com - December 9 at 8:03 AM
Why this $300 million biotech IPO could be huge — or another flop in Alzheimer’s and ALSWhy this $300 million biotech IPO could be huge — or another flop in Alzheimer’s and ALS
www.bizjournals.com - December 8 at 8:02 AM
Denali Therapeutics (DNLI) Prices 13.89M Share IPO at $18/ShDenali Therapeutics (DNLI) Prices 13.89M Share IPO at $18/Sh
www.streetinsider.com - December 8 at 8:02 AM
Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPODenali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO
finance.yahoo.com - December 8 at 8:02 AM
Denali Therapeutics increases deal size of tonights IPO to $250 millionDenali Therapeutics increases deal size of tonight's IPO to $250 million
www.nasdaq.com - December 7 at 7:15 PM
Upsized $300M biotech IPO could be huge — or another flop in Alzheimer’s and ALSUpsized $300M biotech IPO could be huge — or another flop in Alzheimer’s and ALS
www.bizjournals.com - December 7 at 7:15 PM
Denali Therapeutics upsizes IPO, to raise $250 million at midpoint of price rangeDenali Therapeutics upsizes IPO, to raise $250 million at midpoint of price range
www.marketwatch.com - December 7 at 7:15 PM
Denali Therapeutics Announces Pricing of Initial Public OfferingDenali Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - December 7 at 7:15 PM
Bank, Fintech IPOs To Ride The Rotation Into Finance EquitiesBank, Fintech IPOs To Ride The Rotation Into Finance Equities
www.benzinga.com - December 7 at 8:02 AM
Denali Therapeutics Plans $149 Million IPO for December 8th (DNLI)Denali Therapeutics Plans $149 Million IPO for December 8th (DNLI)
www.americanbankingnews.com - November 30 at 1:08 AM

SEC Filings

Denali Therapeutics (NASDAQ:DNLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Denali Therapeutics (NASDAQ DNLI) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.